Thymus, thymoma, and specific T cells in myasthenia gravis

Annals of the New York Academy of Sciences

Volumn 841, Issue , 1998, Pages 371-387

  Beeson, D ^a   Bond, A P ^a   Corlett, L ^a   Curnow, S J ^a   Hill, M E ^a   Jacobson, L W ^a   Maclennan, C ^a   Meager, A ^b   Moody, A M ^a   Moss, P ^a   Nagvekar, N ^a   Newsom Davis, J ^a   Pantic, N ^a   Roxanis, I ^a   Spack, E G ^c   Vincent, A ^a   Willcox, N ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; CYTOKINE ANTIBODY; HLA ANTIGEN CLASS 2; HLA DQ ANTIGEN; NICOTINIC RECEPTOR; RECEPTOR SUBUNIT; RECOMBINANT PROTEIN; T LYMPHOCYTE RECEPTOR;

ALLELE; ANTIBODY RESPONSE; AUTOIMMUNITY; CELLULAR IMMUNITY; CONFERENCE PAPER; EATON LAMBERT SYNDROME; HELPER CELL; HUMAN; IMMUNOTHERAPY; MYASTHENIA GRAVIS; NONHUMAN; PROTEIN GLYCOSYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; THYMOMA; THYMUS FUNCTION; THYMUS HYPERPLASIA;

EID: 0031901967     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1998.tb10950.x     Document Type: Conference Paper

References (58)

1. SOUADJIAN, J. V. et al. 1974. The spectrum of diseases associated with thymoma. Arch. Intern. Med. 134: 373-379.
2. CASTLEMAN, B. & E. H. NORRIS. 1949. The pathology of the thymus gland in myasthenia gravis: a study of 35 cases. Medicine 28: 27-58.
3. WILLCOX, N. & A. VINCENT. 1988. Myasthenia gravis as an example of organ-specific autoimmune disease. In B Lymphocytes in Human Disease, p. 469-506. Oxford University Press. London/New York.
4. BEESON, D. et al. 1993. Primary structure of the human muscle acetylcholine receptor: cDNA cloning of the gamma and epsilon subunits. Eur. J. Biochem. 215: 229-238.
5. FUJII, Y. & J. LINDSTROM. 1988. Specificity of the T cell immune response to acetylcholine receptor in experimental autoimmune myasthenia gravis. J. Immunol. 140: 1830-1837.
6. BELLONE, M. et al. 1991. Experimental myasthenia gravis in congenic mice: sequence mapping and H-2 restriction of T helper epitopes on the α subunits of Torpedo califomica and murine acetylcholine receptors. Eur. J. Immunol. 21: 2303-2310.
7. WILLCOX, N. et al. 1993. Approaches for studying the pathogenic T cells in autoimmune patients. Ann. N.Y. Acad. Sci. 681: 219-237.
8. HAWKE, S. et al. 1996. Autoimmune T cells in myasthenia gravis: heterogeneity and potential for specific immunotargeting. Immunol. Today 17: 307-311.
9. MELMS, A. et al. 1992. T cells from normal and myasthenic individuals recognize the human acetylcholine receptor: heterogeneity of antigenic sites on the α-subunit. Ann. Neurol. 31: 311-318.
10. PROTTI, M. P. et al. 1993. Myasthenia gravis: recognition of a human autoantigen at the molecular level. Immunol. Today 14: 363-368.
11. MATSUO, H. et al. 1995. Recognition of unnatural epitopes by peptide-selected T cell lines in myasthenia gravis patients and controls. J. Immunol. 155: 3683-3692.
12. O'NEILL, J. H., N. M. MURRAY & J. NEWSOM-DAVIS. 1988. The Lambert-Eaton myasthenic syndrome: a review of 50 cases. Brain 111: 577-596.
13. LANG, B. et al. 1981. Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet ii: 224-226.
14. CHALK, C. et al. 1990. Response of the Lambert-Eaton myasthenic syndrome to treatment of associated small-cell lung carcinoma. Neurology 40: 1552-1556.
15. WILLCOX, N. 1993. Myasthenia gravis. Curr. Opin. Immunol. 5: 910-917.
16. CHILOSI, M. et al. 1986. Myasthenia gravis: immunohistological heterogeneity in microenvironmental organization of hyperplastic and neoplastic thymuses suggesting different mechanisms of tolerance breakdown. J. Neuroimmunol. 11: 191-204.
17. NAMBA, T., N. G. BRUNNER & D. GROB. 1978. Myasthenia gravis in patients with thymoma, with particular reference to onset after thymectomy. Medicine 57: 411-433.
18. AARLI, J. A. et al. 1990. Patients with myasthenia gravis and thymoma have in their sera IgG autoantibodies against titin. Clin. Exp. Immunol. 82: 284-288.
19. WILLIAMS, C. L. & V. A. LENNON. 1986. Thymic B lymphocyte clones from patients with myasthenia gravis secrete monoclonal striational antibodies reacting with myosin, alpha-actinin, or actin. J. Exp. Med. 164: 1043-1059.
20. GILHUS, N-E. et al. 1984. Rabbit antiserum to a citric acid extract of human skeletal muscle staining thymomas from myasthenia gravis patients. J. Neuroimmunol. 7: 55-64.
21. HARA, Y. et al. 1991. Neoplastic epithelial cells express α-subunit of muscle nicotinic acetylcholine receptor in thymoma from patients with myasthenia gravis. FEBS Lett. 279: 137-140.
22. WHEATLEY, L. M. et al. 1992. Molecular evidence for the expression of nicotinic acetylcholine receptor α-chain in mouse thymus. J. Immunol. 148: 3105-3109.
23. KIRCHNER, T. et al. 1988. Pathogenesis of myasthenia gravis: acetylcholine receptor-related antigenic determinants in tumor-free thymuses and thymic epithelial tumors. Am. J. Pathol. 130: 268-280.
24. MARX, A. et al. 1990. Characterization of a protein with an acetylcholine receptor epitope from myasthenia gravis-associated thymomas. Lab. Invest. 62: 279-286.
25. MARX, A. et al. 1996. Expression of neurofilaments and of a titin epitope in thymic epithelial tumors. Am. J. Pathol. 148: 1839-1850.
26. TZARTOS, S. J. & M. S. REMOUNDOS. 1992. Precise epitope mapping of monoclonal antibodies to the cytoplasmic side of the acetylcholine receptor a subunit: dissecting a potentially myasthenogenic epitope. Eur. J. Biochem. 207: 915-922.
27. (a) NAGVEKAR, N. et al. 1997. Epitopes expressed in myasthenia gravis thymomas are not recognized by patients' T cells or autoantibodies. Submitted;
28. (b) NAGVEKAR, N. et al. 1997. A pathogenetic role for the thymoma in myasthenia gravis; autosensitization of IL4-producing T cell clones recognizing extracellular acetylcholine receptor epitopes presented by minority class II isotypes. Submitted.
29. MACLENNAN, C. et al. Expression levels of mRNAs encoding acetylcholine receptor sub-units in MG thymus and thymoma. In preparation.
30. MACLENNAN, C. et al. 1997. Expression of muscle acetylcholine receptor mRNA in atypical carcinoid tumors of the thymus. In preparation.
31. MARSH, S. G. E., J. E. MOSES & J. G. BODMER. 1992. HLA class II sequence polymorphism detectable by serology. In HLA 1991, p. 610-620. Oxford University Press. London/New York.
32. MELLINS, E. et al. 1991. A gene required for class II-restricted antigen presentation maps to the major histocompatibility complex. J. Exp. Med. 174: 1607-1615.
33. HENWOOD, J. et al. 1993. Restricted T cell receptor expression by human T cell clones specific for mycobacterial 65-kDa heat-shock protein: selective in vivo expansion of T cells bearing defined receptors. Eur. J. Immunol. 23: 1256-1265.
34. HIGGINS, J. A. et al. 1994. Overlapping T cell epitopes in the group I allergen of Dermatophagoides species restricted by HLA-DP and HLA-DR class II molecules. J. Allergy Clin. Immunol. 93: 891-899.
35. CELIS, E., D. OU & L. Orvos. 1988. Recognition of hepatitis B surface antigen by human T lymphocytes. J. Immunol. 140: 1808-1815.
36. CELIS, E. et al. 1990. Identification of a rabies virus T cell epitope on the basis of its similarity with hepatitis B surface antigen peptide presented to T cells by the same MHC molecule (DPw4). J. Immunol. 145: 305-310.
37. HAMMOND, S. A. et al. 1991. Characterization of a conserved T cell epitope in HIV-1 gp41 recognized by vaccine-induced human cytolytic T cells. J. Immunol. 146: 1470-1477.
38. DE KOSTER, S., D. C. ANDERSON & A. TERMIJTELEN. 1989. T cells sensitized to synthetic HLA-DR3 peptide give evidence of continuous presentation of denatured HLA-DR3 molecules by HLA-DP. J. Exp. Med. 169: 1191-1196.
39. RAMMENSEE, H-G., T. FRIEDE & S. STEVANOVIC. 1995. MHC ligands and peptide motifs: first listing. Immunogenetics 41: 178-228.
40. NAGVEKAR, N. et al. 1997. Mapping an HLA-DR52a-restricted epitope from the human acetylcholine receptor: comparison of natural and artificial epitopes. In preparation.
41. MEAGER, A. et al. 1997. Spontaneous neutralising antibodies to interferon-α and interleukin-12 in thymoma-associated myasthenia gravis. Lancet. In press.
42. ASHERSON, G. L. & A. D. B. WEBSTER. 1980. Thymoma and immunodeficiency. In Diagnosis and Treatment of Immunodeficiency, p. 78-98. Blackwell. Oxford.
43. JANOSSY, G. et al. 1986. Cellular differentiation of lymphoid subpopulations and their microenvironments in the human thymus. Curr. Top. Pathol. 75: 89-125.
44. GRAUS, Y. et al. 1997. Human anti-nicotinic acetylcholine receptor recombinant Fab fragments isolated from thymus-derived phage display libraries from myasthenia gravis patients reflect predominant specificities in serum and block the action of pathogenic serum antibodies. J. Immunol. 158: 1919-1929.
45. FARRAR, J. et al. 1997. Diverse Fabs specific for acetylcholine receptor epitopes from a myasthenia gravis thymus combinatorial library. Int. Immunol. 9: 1311-1318.
46. SCHLUEP, M. et al. 1987. Acetylcholine receptors in human thymic myoid cells in situ: an immunohistological study. Ann. Neurol. 22: 212-222.
47. SCHLUEP, M. et al. 1988. Myasthenia gravis thymus: clinical, histological, and culture correlations. J. Autoimmun, 1: 445-467.
48. + T cell clone from a myasthenia gravis patient. J. Neuroimmunol. 46: 57-66.
49. ALDERUCCIO, F. et al. 1993. An autoimmune disease with multiple molecular targets abrogated by the transgenic expression of a single autoantigen in the thymus. J. Exp. Med. 178:419-426.
50. VAFIADIS, P. et al. 1997. Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. Nat. Genet. 15: 289-292.
51. HILL, M. et al. 1997. T cell responses to the ε subunit of the acetylcholine receptor in myasthenia gravis. In preparation.
52. HILL, M. et al. 1997. Specific T cell responses to D(-)penicillamine in patients with and without myasthenic complications. In preparation.
53. DEGLI-ESPOSTI, M. A. et al. 1992. An approach to the localization of the susceptibility genes for generalized myasthenia gravis by mapping recombinant ancestral haplotypes. Immunogenetics 35: 355-364.
54. STERN, L. J. et al. 1994. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 368: 215-221.
55. HAWKE, S. et al. 1997. Cross-restriction of a T cell clone to HLA-DR alleles associated with rheumatoid arthritis; clues to arthritogenic peptide motifs. In preparation.
56. + lymphocytes by soluble major histocompatibility complex class II-peptide complexes. J. Clin. Invest. 93: 1361-1369.
57. BOND, A. et al. 1997. Diverse patterns of unresponsiveness in an acetylcholine receptor-specific T cell clone from a myasthenia gravis patient after engaging the T cell receptor with three different ligands. J. Neuroimmunol. In press.
58. SPACK, E. G. et al. 1995. Induction of tolerance in experimental autoimmune myasthenia gravis with solubilized MHC class II:acetylcholine receptor peptide complexes. J. Autoimmun. 8: 787-807.